Mandy Lawson

Mandy Lawson

Auto-generated profile, based on publicly available information

Mandy Lawson

AstraZeneca 1 Bioscience, Oncology R&D Cambridge, United Kingdom

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 September 2023 in Cancer Research
Verified
Journal Article
Open access
PDF file
MLMandy Lawson
Mandy Lawson
NCNatalie Cureton
Natalie Cureton
SRSusana Ros
Susana Ros
ACAzadeh Cheraghchi-Bashi
Azadeh Cheraghchi-Bashi
JUJelena Urosevic
Jelena Urosevic
LCLarissa S. Carnevalli
Larissa S. Carnevalli
Oral selective estrogen receptor degraders (SERD) could become the backbone of endocrine therapy (ET) for estrogen receptor–positive (ER+) breast cancer, as they achieve greater inhibition of ER-driven cancers than current ETs and overcome key resistance mechanisms. In this study, we evaluated the preclinical pharmacology and efficacy of the next-generation oral SERD camizestrant (AZD9833) and assessed ER–co-targeting strategies by combining camizestrant with CDK4/6 inhibitors (CDK4/6i) and PI3K/AKT/mTOR-targeted therapy in models of progression on CDK4/6i and/or ET. Camizestrant demonstrated robust and selective ER degradation, modulated ER-regulated gene expression, and induced complete ER antagonism and significant antiproliferation activity in ESR1 wild-type (ESR1wt) and mutant (ESR1m) breast cancer cell lines and patient-derived xenograft (PDX) models. Camizestrant also delivered strong antitumor activity in fulvestrant-resistant ESR1wt and ESR1m PDX models. Evaluation of camizestrant in combination with CDK4/6i (palbociclib or abemaciclib) in CDK4/6-naive and -resistant models, as well as in combination with PI3Kαi (alpelisib), mTORi (everolimus), or AKTi (capivasertib), indicated that camizestrant was active with CDK4/6i or PI3K/AKT/mTORi and that antitumor activity was further increased by the triple combination. The response was observed independently of PI3K pathway mutation status. Overall, camizestrant shows strong and broad antitumor activity in ER+ breast cancer as a monotherapy and when combined with CDK4/6i and PI3K/AKT/mTORi. Significance: Camizestrant, a next-generation oral SERD, shows promise in preclinical models of ER+ breast cancer alone and in combination with CDK4/6 and PI3K/AKT/mTOR inhibitors to address endocrine resistance, a current barrier to treatment.

29 May 2012 in Pulmonary Pharmacology & Therapeutics
Verified
Journal Article
Closed access
DND.J. Nicholls
D.J. Nicholls
SJS. Jordan
S. Jordan
ECElaine Cadogan
Elaine Cadogan
MLM. Lawson
M. Lawson
RAR.P. Austin
R.P. Austin
AYA. Young
A. Young

26 March 2026 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
PDF file
ABAzadeh C. Bashi
Azadeh C. Bashi
TPTheresa A. Proia
Theresa A. Proia
MLMandy Lawson
Mandy Lawson
ANAnders Nelson
Anders Nelson
LILucy Ireland
Lucy Ireland
SBSimon T. Barry
Simon T. Barry
Trastuzumab deruxtecan (T-DXd), an antibody–drug conjugate composed of an anti-HER2 antibody and a cytotoxic topoisomerase I inhibitor, is approved for the treatment of HER2-positive (HER2+) and HER2-low breast cancer as well as HER2-high gastric and HER2-mutant lung cancer tumors. The AKT inhibitor capivasertib is approved for the treatment of HER2− estrogen receptor–positive breast cancer with alterations in PIK3CA, PTEN, and AKT-1. The potential for the combination of T-DXd with AKT inhibition to enhance antitumor activity was explored in HER2+ or HER2-low preclinical models. In vitro, combination activity was observed in both HER2-high– and HER2-low–expressing breast cancer as well as in gastric, endometrial, and ovarian models, irrespective of HER2 expression level or PI3K–AKT status pathway alterations. The T-DXd–capivasertib combination effect translated in vivo with increased antitumor benefit in HER2-expressing, PI3K–AKT pathway–altered tumor xenografts when compared with the combination of trastuzumab and capivasertib. In cell lines sensitive to the combination, combining T-DXd with capivasertib targeted complimentary pathways which resulted in disruption of the cell cycle and increased cell death. These results suggest that T-DXd combined with capivasertib has the potential to be active in HER2+ as well as HER2-low tumors independent of PI3K pathway alteration status.

2 July 2026
Verified
Other
Open access
PDF file
ABAzadeh C. Bashi
Azadeh C. Bashi
TPTheresa A. Proia
Theresa A. Proia
MLMandy Lawson
Mandy Lawson
ANAnders Nelson
Anders Nelson
LILucy Ireland
Lucy Ireland
SBSimon T. Barry
Simon T. Barry
Supplementary Table 4. Summary of data from selected breast and gastric cell panel in vitro screen for capivasertib, exatecan, trastuzumab (Herceptin) and combination treatment.

2 July 2026
Verified
Other
Open access
ABAzadeh C. Bashi
Azadeh C. Bashi
TPTheresa A. Proia
Theresa A. Proia
MLMandy Lawson
Mandy Lawson
ANAnders Nelson
Anders Nelson
LILucy Ireland
Lucy Ireland
SBSimon T. Barry
Simon T. Barry
Supplementary Figure 16. In vitro activity of capivasertib plus T-DXd in cell lines used for in vivo studies

3 April 2023
Verified
Other
Open access
WTWeiyi Toy
Weiyi Toy
HWHazel Weir
Hazel Weir
PRPedram Razavi
Pedram Razavi
MLMandy Lawson
Mandy Lawson
AGAnne U. Goeppert
Anne U. Goeppert
SCSarat Chandarlapaty
Sarat Chandarlapaty